Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
← catalyst calendarNCT04533581 · readout in 651 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
61actual
Sites
30
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-17 | actual | When the study began enrolling |
| Primary completion | 2028-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Indolent B-cell Non-Hodgkin's Lymphoma
Intervention
- Drug: ME-401
Primary outcome
what the primary-completion date above is the date OFObjective response rate (ORR)
measured Up to approximately 2 years
Publications
- PMID 39778876 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed